12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sufentanil NanoTab PCA System: Phase III started

AcelRx began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 15 µg sublingual Sufentanil NanoTabs given every 20 minutes via Sufentanil NanoTab PCA System...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >